menu
    • menu

    Company profile for Recludix Pharma

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is advancing another...
    Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is advancing another program with an undisclosed non-STAT SH2 domain target that also plays a significant role in both cancer and autoimmune diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Recludix PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3525 John Hopkins Court, Suite 150 San Diego, CA 92121
    Telephone
    Telephone
    +1 8582585445
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://recludixpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/recludix-pharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Recludix Pharma Secures Funds For Novel SH2 Domain Inhibitors
    Recludix Pharma Secures Funds For Novel SH2 Domain Inhibitors

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216867/0/en/Recludix-Pharma-Announces-Equity-Financing-to-Advance-Clinical-Development-of-Novel-SH2-Domain-Inhibitors.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Recludix Doses First Subjects in Phase 1 STAT6 Inhibitor Study
    Recludix Doses First Subjects in Phase 1 STAT6 Inhibitor Study

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216802/0/en/Recludix-Pharma-Announces-Dosing-of-First-Subjects-in-a-Phase-1-Study-of-REX-8756-a-Potent-and-Selective-Oral-STAT6-Inhibitor-and-Achieves-Associated-20-Million-Milestone-Payment-U.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Recludix Pharma Strengthens Scientific Advisory Board
    Recludix Pharma Strengthens Scientific Advisory Board

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215297/0/en/Recludix-Pharma-Bolsters-Scientific-Advisory-Board-with-Acclaimed-Leaders-in-the-Fields-of-Rheumatology-Dermatology-and-JAK-STAT-Biology.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Recludix Pharma To Present At J.P. Morgan Healthcare Conference
    Recludix Pharma To Present At J.P. Morgan Healthcare Conference

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214489/0/en/Recludix-Pharma-to-Present-at-the-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Recludix Pharma Clears FDA For REX-8756, Oral STAT6 Inhibitor
    Recludix Pharma Clears FDA For REX-8756, Oral STAT6 Inhibitor

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206147/0/en/Recludix-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-REX-8756-an-Oral-STAT6-Inhibitor-to-Enter-into-the-Clinic.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Recludix Pharma To Present at 2 Investor Conferences In November
    Recludix Pharma To Present at 2 Investor Conferences In November

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179171/0/en/Recludix-Pharma-to-Present-at-Two-Investor-Conferences-in-November.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search